D vitamini düzeyi ile paraoksonaz 1 enzim aktivitesi arasındaki ilişki

Yıl 2019, , 199 - 206, 06.02.2020

Özge Dokuzlar Mehmet Calan Ali Şişman Sinem Kocaer Fırat Bayraktar

https://doi.org/10.5505/deutfd.2019.63644

Öz

Amaç: D vitamini eksikliği lipid metabolizması üzerine olumsuz etki
oluşturmakta ve kardiyovasküler riski artırmaktadır. Paraoksonaz-1 (PON1)
enzim aktivitesi, yüksek dansiteli lipoprotein (HDL) aktivitesini belirleyen
faktörlerden birisidir. Bu araştırmada, D vitamin düzeyi ile PON1 aktivitesi
arasında ilişkili olup olmadığının incelenmesi amaçlandı.
Gereç ve Yöntem: Çalışmamıza 18-50 yaş arası, benzer demografik özelliklere
sahip 200 sağlıklı birey alındı. Araştırmaya dahil edilen bireyler serum 25(OH)D
vitamini düzeyine göre D vitamini düzeyi normal (>30 ng/dL), D vitamin
eksikliği olan (20-30 ng/dL), D vitamin yetmezliği olan (10-20 ng/dL) ve derin D
vitamin yetmezliği olan (<10 ng/dL) bireyler olarak 4 gruba ayrıldı. Bu dört grup
arasında PON1 enzim aktivitesi düzeyi karşılaştırıldı. Plazma PON1 enzim
aktivitesi ELISA yöntemi ile ölçüldü.
Bulgular: Araştırmamıza dahil olan bireylerin 132’si kadın ve 68’i erkek idi.
PON1 enzim aktivitesi 4 grup arasında istatistiksel anlamlı bir fark oluşturmadı.
Ayrıca PON1 enzim aktivitesi ile diğer parametreler arasında da herhangi bir
ilişki saptanmadı.
Sonuç: D vitamini düzeyi ile PON1 enzim aktivitesi arasında bir ilişki
saptanmadı.

Anahtar Kelimeler

D vitamini eksikliği, HDL kolesterol, lipid metabolizması, Paraoksonaz-1

RELATIONSHIP BETWEEN VITAMIN D LEVEL AND PARAOXONASE 1 ENZYME ACTIVITY

Öz

Objective: Vitamin D deficiency has a negative effect on lipid metabolism and
increases cardiovascular risk. Paraoxonase-1 (PON1) enzyme activity is one of
the determinants of high-density lipoprotein (HDL) activity. The aim of this
study was to investigate whether vitamin D level and PON1 activity are related.
Material and Method: 200 healthy individuals between 18-50 years of age with
similar demographic characteristics were included. Individuals included in the
study were divided into four groups as vitamin D levels: sufficient (>30 ng/dL),
mild-moderate deficiency (20-30 ng/dL), deficiency (10-20 ng/dL) and severe
deficiency (<10 ng/dL). PON1 enzyme activity of these four groups was
compared. Plasma PON1 enzyme activity was measured by ELISA.
Results: Of the individuals included to this study, 132 were female and 68 were
male. PON1 enzyme activity did not show any statistically significant difference
between these 4 groups. There was not any relationship between PON1 enzyme
activity and other parameters.
Conclusion: There was no relationship between vitamin D levels and PON1
enzyme activity.

Anahtar Kelimeler

Vitamin D deficiency, HDL Cholesterol, lipid metabolism, Paraoxonase-1

Kaynakça

• 1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
• 2. Mozos I, Marginean O. Links between Vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015;2015:109275.
• 3. Reid IR, Bolland MJ. Role of vitamin D deficiency in cardiovascular disease. Heart. 2012;98(8):609–14.
• 4. Lavie CJ, Lee JH, Milani R V. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol. 2011;58(15):1547–56.
• 5. Sahota O. Understanding vitamin D deficiency. Age Ageing. 2014;43(5):589–91.
• 6. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12.
• 7. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.
• 8. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14.
• 9. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31.
• 10. Thomas GN, Hartaigh BÓ, Bosch JA, Pilz S, Loerbroks A, Kleber ME, et al. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: The Ludwigshafen risk and cardiovascular health (LURIC) study. Diabetes Care. 2012;35(5):1158–64.
• 11. Uysal S, Akyol S, Hasgül R, Armutcu F, Yiğitoğlu F. Çok Yönlü Bir Enzim: Paraoksonaz. Yeni Tıp Derg. 2011;28(3):136–41.
• 12. Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int J Mol Sci. 2019;20(16):pii: E4049.
• 13. Tarcin O. Paraoxonase-1 And Coronary Heart Diseases. Marmara Med J. 2010;24(1):59–63.
• 14. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. J Biol Chem. 2001;354:1–7.
• 15. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, et al. Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes that Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxvnitrite Donor. J Biol Chem. 2001;276(27):24473.
• 16. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem. 2000;275(6):3957–62.
• 17. Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact. 2016;259:51–62.
• 18. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.
• 19. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541–50.
• 20. Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, et al. Paraoxonase 1: Genetics and Activities During Aging. Rejuvenation Res. 2008;11:113–27.
• 21. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
• 22. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
• 23. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
• 24. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
• 25. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol. 2004;15:399–404.
• 26. Kıdır V. D Vitamininin kardiyovasküler ve metabolik etkileri. J Clin Exp Invest. 2013;4(3):398–404.
• 27. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31(3):329–36.
• 28. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90(3):1728–3.
• 29. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97(7):1630–9.
• 30. Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, et al. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2019;
• 31. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8.
• 32. C. Brewer L, D. Michos E, P. Reis J. Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function. Curr Drug Targets. 2011;12:54–60.
• 33. Mutt SJ, Jokelainen J, Sebert S, Auvinen J, Järvelin MR, Keinänen-Kiukaanniemi S, et al. Vitamin D status and components of metabolic syndrome in older subjects from Northern Finland (Latitude 65◦North). Nutrients. 2019;11(6):pii: E1229.
• 34. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol Hyperten. 2011;20(4):345–53.
• 35. Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers. 2013;35(2):97–103.
• 36. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.